Altered levels of circulating nuclear and mitochondrial DNA in patients with Papillary Thyroid Cancer.
Ewelina PerdasRobert StawskiKrzysztof KaczkaDariusz NowakMaria ZubrzyckaPublished in: Scientific reports (2019)
Papillary thyroid cancer is the most common thyroid cancer type. However, diagnostics based on fine needle biopsy cannot make a definitive diagnosis in 25% of thyroid nodules. Additionally, approximately 70% to 80% of thyroid lobectomies performed just for diagnostic purposes are benign. Despite this, biopsy still remains the main method of evaluation of thyroid nodules. Cell-free DNA (cf-DNA) measurement could give a new diagnostic opportunities which may reduce the number of unnecessary thyroid procedures. In this study, using a qPCR, we have examined the nuclear cf-DNA and mitochondrial cf-DNA in the plasma of 32 patients. We have found that the level of nuclear cf-DNA is almost 2-fold increased (median 3 089 vs. 1 872, p = 0.022), whereas mitochondrial cf-DNA content was significantly decreased in respect to healthy controls (median 44 992 vs. 92 220, p = 0.010). The ROC curve analysis showed high specificity for nuclear cf-DNA and mitochondrial cf-DNA, which may serve as a useful tool to decrease the number of unneeded surgeries. Our study reports the first epidemiological evidence for lower mitochondrial cf-DNA content in the patient group, what suggests that apart from nuclear cf-DNA also mitochondrial cf-DNA is affected by disease development.
Keyphrases
- circulating tumor
- cystic fibrosis
- papillary thyroid
- cell free
- single molecule
- oxidative stress
- mitochondrial dna
- lymph node metastasis
- nucleic acid
- circulating tumor cells
- newly diagnosed
- gene expression
- end stage renal disease
- case report
- chronic kidney disease
- rectal cancer
- patient reported outcomes
- squamous cell
- electronic health record
- adverse drug